NZ223529A - (r-(e))-4-(3-phosphono-2-propenyl)-2-piperazinecarboxylic acid and salts and pharmaceutical compositions - Google Patents

(r-(e))-4-(3-phosphono-2-propenyl)-2-piperazinecarboxylic acid and salts and pharmaceutical compositions

Info

Publication number
NZ223529A
NZ223529A NZ223529A NZ22352988A NZ223529A NZ 223529 A NZ223529 A NZ 223529A NZ 223529 A NZ223529 A NZ 223529A NZ 22352988 A NZ22352988 A NZ 22352988A NZ 223529 A NZ223529 A NZ 223529A
Authority
NZ
New Zealand
Prior art keywords
phosphono
propenyl
salts
pharmaceutical compositions
piperazinecarboxylic acid
Prior art date
Application number
NZ223529A
Other languages
English (en)
Inventor
Bernhard Aebischer
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of NZ223529A publication Critical patent/NZ223529A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ223529A 1987-02-18 1988-02-16 (r-(e))-4-(3-phosphono-2-propenyl)-2-piperazinecarboxylic acid and salts and pharmaceutical compositions NZ223529A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878703749A GB8703749D0 (en) 1987-02-18 1987-02-18 Piperazinecarboxylic acid

Publications (1)

Publication Number Publication Date
NZ223529A true NZ223529A (en) 1991-02-26

Family

ID=10612501

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ223529A NZ223529A (en) 1987-02-18 1988-02-16 (r-(e))-4-(3-phosphono-2-propenyl)-2-piperazinecarboxylic acid and salts and pharmaceutical compositions

Country Status (28)

Country Link
JP (1) JPH0723387B2 (fr)
KR (1) KR960015190B1 (fr)
AT (1) AT391320B (fr)
AU (1) AU613009B2 (fr)
BE (1) BE1002427A3 (fr)
CA (1) CA1327799C (fr)
CH (1) CH675125A5 (fr)
CY (1) CY1739A (fr)
DE (1) DE3804936C2 (fr)
DK (1) DK168441B1 (fr)
ES (2) ES2011319A6 (fr)
FI (1) FI86733C (fr)
FR (1) FR2610932B1 (fr)
GB (2) GB8703749D0 (fr)
GR (1) GR1002471B (fr)
HK (1) HK142093A (fr)
HU (2) HU199858B (fr)
IE (1) IE59098B1 (fr)
IL (1) IL85436A0 (fr)
IT (1) IT1219447B (fr)
LU (1) LU87129A1 (fr)
MY (1) MY103206A (fr)
NL (1) NL8800412A (fr)
NZ (1) NZ223529A (fr)
PH (1) PH25512A (fr)
PT (1) PT86776B (fr)
SE (1) SE467256B (fr)
ZA (1) ZA881146B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202111B (en) * 1988-03-11 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0488959A3 (en) * 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
JPH11508761A (ja) * 1995-05-08 1999-08-03 ロンザ アーゲー R−α−ピペラジンカルボン酸およびS−α−ピペラジンカルボキサミドを製造する生物工学的方法
US6071915A (en) 1997-05-12 2000-06-06 Ortho-Mcneil Pharmaceutical, Inc. Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
JP2008124531A (ja) 2006-11-08 2008-05-29 Nec Electronics Corp 半導体装置およびオーディオプロセッサチップ
EP3427729A1 (fr) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probénécide destiné à être utilisé dans le traitement de maladies, troubles ou états épileptiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (fr) * 1984-04-17 1989-01-10 Jeffrey C. Watkins Derives de substitution en 4 d'acides piperazine-2- carboxyliques

Also Published As

Publication number Publication date
IE59098B1 (en) 1994-01-12
SE8800541D0 (sv) 1988-02-17
FI86733B (fi) 1992-06-30
CH675125A5 (fr) 1990-08-31
CA1327799C (fr) 1994-03-15
PT86776B (pt) 1992-05-29
KR880009944A (ko) 1988-10-06
GB8803438D0 (en) 1988-03-16
AU613009B2 (en) 1991-07-25
DE3804936C2 (de) 1997-02-13
IL85436A0 (en) 1988-07-31
MY103206A (en) 1993-05-29
JPH0723387B2 (ja) 1995-03-15
GB2201676A (en) 1988-09-07
GR880100084A (el) 1988-12-16
FR2610932A1 (fr) 1988-08-19
IT8847631A0 (it) 1988-02-12
SE467256B (sv) 1992-06-22
DE3804936A1 (de) 1988-09-01
DK168441B1 (da) 1994-03-28
FI880744A (fi) 1988-08-19
ES2011319A6 (es) 1990-01-01
CY1739A (en) 1995-10-20
BE1002427A3 (fr) 1991-02-05
ATA36788A (de) 1990-03-15
ZA881146B (en) 1989-10-25
HUT49361A (en) 1989-09-28
GB2201676B (en) 1991-01-02
HU199858B (en) 1990-03-28
FR2610932B1 (fr) 1990-11-16
AU1175888A (en) 1988-08-25
ES2021904A6 (es) 1991-11-16
LU87129A1 (fr) 1988-09-20
HK142093A (en) 1994-01-07
HU211269A9 (en) 1995-11-28
FI86733C (fi) 1992-10-12
GR1002471B (el) 1996-11-15
AT391320B (de) 1990-09-25
DK79688D0 (da) 1988-02-16
PH25512A (en) 1991-07-24
PT86776A (pt) 1988-03-01
DK79688A (da) 1988-08-19
IL85436A (fr) 1992-12-01
SE8800541A (fr) 1988-08-19
IT1219447B (it) 1990-05-18
KR960015190B1 (ko) 1996-11-01
NL8800412A (nl) 1988-09-16
IE880413L (en) 1988-08-18
GB8703749D0 (en) 1987-03-25
FI880744A0 (fi) 1988-02-17
JPS63203691A (ja) 1988-08-23

Similar Documents

Publication Publication Date Title
IL84105A0 (en) 1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acids and salts thereof and pharmaceutical compositions containing them
IL87079A0 (en) Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them
GB8710965D0 (en) Pharmaceutical compositions
IL85896A (en) Substituted di-tert.- butylphenols and pharmaceutical compositions containing them
NZ226002A (en) Peptidylheterocyclic compounds and pharmaceutical compositions
IL85969A0 (en) Ribofuranuronic acid derivatives and pharmaceutical compositions containing them
IL87800A0 (en) Dioxolane-2-carboxylic acids and pharmaceutical compositions comprising them
EG18652A (en) Pharmaceutical compositions
NZ226450A (en) Crystalline-1-carbacephalosporin and pharmaceutical compositions
NZ223529A (en) (r-(e))-4-(3-phosphono-2-propenyl)-2-piperazinecarboxylic acid and salts and pharmaceutical compositions
NZ224923A (en) 2-methoxymethyl-penem-3-carboxylic acid derivatives and pharmaceutical compositions
NZ218614A (en) 16,17-butylidenedioxy-6,9-difluoro-11-hydroxy-3, 20-dioxopregna-1,4-diene-21-oic acid esters and pharmaceutical compositions
IL93590A0 (en) Acid addition salts of naphthalenmethanamino and pharmaceutical compositions containing them
NZ221018A (en) 2-penem-3-carboxylic acid derivatives and pharmaceutical compositions
GB8713091D0 (en) Pharmaceutical compositions
NZ238848A (en) Sulphur-substituted mevinic acid compounds and pharmaceutical compositions
IL94937A0 (en) Pharmaceutical compositions containing acrylic acid derivatives
IL85524A0 (en) Heterocyclyl-2-propyn-1-amines and pharmaceutical compositions containing same
ZA888097B (en) Phthalazineacetic acid composition and tablet
NZ223138A (en) 2,1-benzothiazepine-2,2-dioxide-5-carboxylic acid derivatives and pharmaceutical compositions
CY1752A (en) 8a-Acylaminoergoline its preparation and pharmaceutical compositions containing it
NZ226451A (en) Crystalline 1-carbacephalosporins and pharmaceutical compositions
IL93649A0 (en) Pharmaceutical composition containing n-acetylneuraminic acid
GB8728689D0 (en) Amino acid pharmaceutical compositions
IL102620A0 (en) Benzeneethanamines and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409